Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), with a mix of bullish, indifferent, and bearish perspectives. The average 12-month price target has decreased by 25.64% to $40.4. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance.
May 31, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have mixed ratings on Calliditas Therapeutics (NASDAQ:CALT) with a notable decrease in the average 12-month price target by 25.64% to $40.4. Recent ratings include neutral and hold positions, reflecting cautious sentiment.
The decrease in the average 12-month price target and the mixed ratings from analysts indicate a cautious outlook on Calliditas Therapeutics. This could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100